JP2017523805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523805A5 JP2017523805A5 JP2017523183A JP2017523183A JP2017523805A5 JP 2017523805 A5 JP2017523805 A5 JP 2017523805A5 JP 2017523183 A JP2017523183 A JP 2017523183A JP 2017523183 A JP2017523183 A JP 2017523183A JP 2017523805 A5 JP2017523805 A5 JP 2017523805A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- lcdr
- hcdr
- antibody
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 77
- 239000000427 antigen Substances 0.000 claims description 73
- 102000036639 antigens Human genes 0.000 claims description 73
- 108091007433 antigens Proteins 0.000 claims description 73
- 241000713196 Influenza B virus Species 0.000 claims description 26
- 101710154606 Hemagglutinin Proteins 0.000 claims description 18
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 18
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 18
- 101710176177 Protein A56 Proteins 0.000 claims description 18
- 239000000185 hemagglutinin Substances 0.000 claims description 18
- 230000003472 neutralizing effect Effects 0.000 claims description 15
- 208000037798 influenza B Diseases 0.000 claims description 14
- 101900234398 Influenza B virus Hemagglutinin Proteins 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 241000712431 Influenza A virus Species 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 208000037797 influenza A Diseases 0.000 claims description 8
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 241000713174 Influenza B virus (B/Ann Arbor/1/1966 [wild- type]) Species 0.000 claims description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims 3
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 claims 1
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024804P | 2014-07-15 | 2014-07-15 | |
| US62/024,804 | 2014-07-15 | ||
| PCT/US2015/040385 WO2016011035A2 (en) | 2014-07-15 | 2015-07-14 | Neutralizing anti-influenza b antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018692A Division JP7209754B2 (ja) | 2014-07-15 | 2021-02-09 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523805A JP2017523805A (ja) | 2017-08-24 |
| JP2017523805A5 true JP2017523805A5 (OSRAM) | 2018-08-23 |
| JP6837434B2 JP6837434B2 (ja) | 2021-03-03 |
Family
ID=55079157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523183A Active JP6837434B2 (ja) | 2014-07-15 | 2015-07-14 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2021018692A Active JP7209754B2 (ja) | 2014-07-15 | 2021-02-09 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2023001445A Active JP7453430B2 (ja) | 2014-07-15 | 2023-01-10 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2024034654A Pending JP2024069341A (ja) | 2014-07-15 | 2024-03-07 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018692A Active JP7209754B2 (ja) | 2014-07-15 | 2021-02-09 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2023001445A Active JP7453430B2 (ja) | 2014-07-15 | 2023-01-10 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2024034654A Pending JP2024069341A (ja) | 2014-07-15 | 2024-03-07 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10294292B2 (OSRAM) |
| EP (1) | EP3169407A4 (OSRAM) |
| JP (4) | JP6837434B2 (OSRAM) |
| CN (4) | CN106573154B (OSRAM) |
| AU (3) | AU2015289805B2 (OSRAM) |
| BR (1) | BR112017000640A2 (OSRAM) |
| CA (1) | CA2954780A1 (OSRAM) |
| MX (3) | MX392761B (OSRAM) |
| RU (2) | RU2739952C2 (OSRAM) |
| WO (1) | WO2016011035A2 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60938B1 (sr) * | 2013-10-02 | 2020-11-30 | Medimmune Llc | Neutrališuća antitela na grip a i njihova upotreba |
| WO2016011035A2 (en) | 2014-07-15 | 2016-01-21 | Medlmmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| PT3303384T (pt) | 2015-06-01 | 2021-10-14 | Medimmune Llc | Moléculas de ligação neutralizantes anti-influenza e suas utilizações |
| IL304940A (en) | 2016-01-13 | 2023-10-01 | Medimmune Llc | A method for treating type A influenza |
| PH12022550963A1 (en) * | 2019-10-28 | 2023-09-25 | Regeneron Pharma | Anti-hemagglutinin antibodies and methods of use thereof |
| CN112048006B (zh) * | 2020-09-08 | 2021-04-27 | 扬州大学 | 一种替代中和效力测定的elisa方法及其应用 |
| US20250320279A1 (en) * | 2021-11-30 | 2025-10-16 | Sab, Llc | Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof |
| CN118420751B (zh) * | 2022-07-09 | 2025-04-08 | 东莞市朋志生物科技有限公司 | 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US6071251A (en) | 1996-12-06 | 2000-06-06 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6300104B1 (en) | 1997-06-19 | 2001-10-09 | The Regents Of The University Of California | Secretory immunoglobulin produced by single cells and methods for making and using same |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| WO2000059932A1 (fr) * | 1999-03-31 | 2000-10-12 | Otsuka Pharmaceutical Co., Ltd. | Peptides se liant a l'hemagglutinine du virus de la grippe |
| JP4656478B2 (ja) | 2000-02-22 | 2011-03-23 | 株式会社医学生物学研究所 | 抗体ライブラリー |
| ATE309385T1 (de) | 2000-06-28 | 2005-11-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1551875A4 (en) | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
| AU2003251809A1 (en) | 2002-07-11 | 2004-02-02 | The General Hospital Corporation | Polynucleotide and polypeptide fat metabolism regulators and uses thereof |
| EP3321282A1 (en) | 2002-09-27 | 2018-05-16 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| WO2005007697A1 (ja) | 2003-07-23 | 2005-01-27 | Fujirebio Inc. | 抗インフルエンザａ型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具 |
| CN103446582A (zh) | 2003-08-11 | 2013-12-18 | 财团法人阪大微生物病研究会 | 包含诱导粘膜免疫的佐剂的新型疫苗 |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| NZ598048A (en) | 2006-01-17 | 2013-05-31 | Synthon Biopharmaceuticals Bv | Compositions and methods for humanization and optimization of n-glycans in plants |
| AU2007226856A1 (en) | 2006-03-21 | 2007-09-27 | Michael Rynkiewicz | Methods for humanizing antibodies and humanized antibodies made thereby |
| WO2007117577A2 (en) | 2006-04-07 | 2007-10-18 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-18 receptor |
| US20080014205A1 (en) | 2006-05-15 | 2008-01-17 | Lawrence Horowitz | Neutralizing Antibodies to Influenza Viruses |
| EA017203B1 (ru) | 2006-09-07 | 2012-10-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение |
| PL2069403T3 (pl) | 2006-10-02 | 2015-08-31 | Regeneron Pharma | Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4 |
| JP5601836B2 (ja) | 2006-11-08 | 2014-10-08 | マクロジェニックス ウエスト， インコーポレイテッド | Ｔｅｓ７およびｔｅｓ７に結合する抗体 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| EP2125886A2 (en) | 2007-03-13 | 2009-12-02 | Humabs LLC | Antibodies against h5n1 strains of influenza a virus |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| RU2553325C2 (ru) * | 2008-07-25 | 2015-06-10 | Институт Фо Ресёч Ин Биомедицин | Нейтрализующие антитела против вируса гриппа а и их использование |
| WO2010027818A2 (en) | 2008-08-25 | 2010-03-11 | Dana-Farber Cancer Institute, Inc. | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
| CA2742969A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| US9534042B2 (en) * | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| AU2011344126B2 (en) | 2010-12-13 | 2016-11-10 | The University Of Utah Research Foundation | Vaccine antigens that direct immunity to conserved epitopes |
| US8961978B2 (en) | 2011-07-14 | 2015-02-24 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses |
| MX352338B (es) | 2011-07-18 | 2017-11-17 | Inst Res Biomedicine | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. |
| AU2012312529B2 (en) | 2011-09-20 | 2018-01-04 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| WO2013044203A2 (en) | 2011-09-23 | 2013-03-28 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES | Novel influenza hemagglutinin protein-based vaccines |
| EP2776061B1 (en) * | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
| CA2861515A1 (en) | 2011-12-05 | 2013-06-13 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
| US8834881B2 (en) * | 2012-03-08 | 2014-09-16 | Crucell Holland B.V. | Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof |
| BR112015010817A8 (pt) * | 2012-11-13 | 2018-01-23 | Genentech Inc | anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| RU2536956C1 (ru) | 2013-08-05 | 2014-12-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" | Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а |
| RS60938B1 (sr) | 2013-10-02 | 2020-11-30 | Medimmune Llc | Neutrališuća antitela na grip a i njihova upotreba |
| WO2016011035A2 (en) * | 2014-07-15 | 2016-01-21 | Medlmmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| PT3303384T (pt) | 2015-06-01 | 2021-10-14 | Medimmune Llc | Moléculas de ligação neutralizantes anti-influenza e suas utilizações |
| IL304940A (en) | 2016-01-13 | 2023-10-01 | Medimmune Llc | A method for treating type A influenza |
| CN109195629A (zh) | 2016-02-24 | 2019-01-11 | 威特拉公司 | 流行性感冒抗体分子制剂 |
-
2015
- 2015-07-14 WO PCT/US2015/040385 patent/WO2016011035A2/en not_active Ceased
- 2015-07-14 RU RU2020100073A patent/RU2739952C2/ru active
- 2015-07-14 BR BR112017000640A patent/BR112017000640A2/pt not_active Application Discontinuation
- 2015-07-14 CN CN201580038244.1A patent/CN106573154B/zh active Active
- 2015-07-14 RU RU2017104638A patent/RU2711932C2/ru active
- 2015-07-14 CN CN202410982380.7A patent/CN119161468A/zh active Pending
- 2015-07-14 EP EP15821645.7A patent/EP3169407A4/en active Pending
- 2015-07-14 JP JP2017523183A patent/JP6837434B2/ja active Active
- 2015-07-14 CN CN202110634379.1A patent/CN113563462B/zh active Active
- 2015-07-14 US US15/325,603 patent/US10294292B2/en active Active
- 2015-07-14 MX MX2017000595A patent/MX392761B/es unknown
- 2015-07-14 AU AU2015289805A patent/AU2015289805B2/en active Active
- 2015-07-14 CN CN202110634430.9A patent/CN113173990B/zh active Active
- 2015-07-14 CA CA2954780A patent/CA2954780A1/en active Pending
-
2017
- 2017-01-13 MX MX2022006561A patent/MX2022006561A/es unknown
- 2017-01-13 MX MX2022006558A patent/MX2022006558A/es unknown
-
2019
- 2019-03-22 US US16/361,653 patent/US10519221B2/en active Active
- 2019-11-07 US US16/676,974 patent/US11174304B2/en active Active
-
2020
- 2020-09-15 AU AU2020233635A patent/AU2020233635B2/en active Active
-
2021
- 2021-02-09 JP JP2021018692A patent/JP7209754B2/ja active Active
- 2021-10-12 US US17/499,495 patent/US11787853B2/en active Active
-
2023
- 2023-01-10 JP JP2023001445A patent/JP7453430B2/ja active Active
- 2023-09-08 US US18/463,736 patent/US12325740B2/en active Active
-
2024
- 2024-03-07 JP JP2024034654A patent/JP2024069341A/ja active Pending
- 2024-04-08 AU AU2024202231A patent/AU2024202231A1/en active Pending
-
2025
- 2025-05-08 US US19/202,812 patent/US20250263470A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240425617A1 (en) | Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies | |
| JP2017523805A5 (OSRAM) | ||
| US11926657B2 (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| JP2016538876A5 (OSRAM) | ||
| RU2017104638A (ru) | Нейтрализующие антитела к вирусу гриппа B и пути их применения | |
| JP6371222B2 (ja) | インフルエンザの受動免疫用抗体 | |
| CN115515976A (zh) | 冠状病毒抗体 | |
| JP2018514193A5 (OSRAM) | ||
| WO2018213097A1 (en) | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof | |
| HK40061503B (zh) | 中和抗流感结合分子及其用途 | |
| HK40061503A (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| HK40069730A (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| WO2024108088A1 (en) | Lag-3 and pd-1/lag-3-antibodies | |
| HK40040395B (zh) | 用於治疗癌症的组合物和方法 | |
| HK1250725B (zh) | 中和抗流感结合分子及其用途 | |
| HK1253092B (en) | Neutralizing anti-influenza binding molecules and uses thereof |